3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
9
Active not recruiting
5
Unknown
2
Withdrawn
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
2
Castration-resistant Prostate Cancer
1
Interventions
Docetaxel
21
Radiosurgery
19
Radiotherapy
17
Androgen Antagonists
14
Leuprolide
11
Goserelin
11
bicalutamide
9
enzalutamide
8
Surveys and Questionnaires
8
Prednisone
8
Brachytherapy
8
Blood Specimen Collection
8
Abiraterone Acetate
8
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
7
Radiotherapy, Intensity-Modulated
7
Multiparametric Magnetic Resonance Imaging
7
Gonadotropin-Releasing Hormone
7
Triptorelin Pamoate
6
pembrolizumab
4
cabazitaxel
4
abiraterone
4
Standard of Care
4
Positron Emission Tomography Computed Tomography
4
Metformin
4
Heavy Ion Radiotherapy
4
Exercise
4
Estramustine
4
luprolide acetate gel depot
3
darolutamide
3
Watchful Waiting
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
Prostatic Neoplasms
×
Radium-223
×
Clear all
NCT03432949
2024-01-24
TRANCE
University Health Network, Toronto
Phase 4
Unknown
24 enrolled
NCT04110782
2019-10-01
RaProRad
Azienda Policlinico Umberto I
Unknown
400 enrolled